kabutan

RaQualia Pharma Inc.(4579) Summary

4579
TSE Growth
RaQualia Pharma Inc.
782
JPY
-9
(-1.14%)
Apr 30, 9:01 am JST
4.88
USD
Apr 29, 8:01 pm EDT
Result
PTS
outside of trading hours
786
Apr 28, 9:48 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.97
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
783 JPY 4.88 USD
Previous Close Apr 28
791 JPY 4.96 USD
High Apr 30, 9:01 am
785 JPY 4.90 USD
Low Apr 30, 9:01 am
782 JPY 4.88 USD
Volume
2,600
Trading Value
2.00M JPY 0.01M USD
VWAP
783.04 JPY 4.9 USD
Minimum Trading Value
78,200 JPY 488 USD
Market Cap
0.02T JPY 0.13B USD
Number of Trades
5
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
High
1-Year Average
1,438
1-Year High Dec 2, 2025
41,024
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 2,559,600
Apr 17, 2026 0 2,527,800
Apr 10, 2026 0 2,414,300
Apr 3, 2026 0 2,393,300
Mar 27, 2026 0 2,424,100
Company Profile
RaQualia Pharma Inc. is a drug discovery venture company specializing in pain disorders. Its main revenue source is the out-licensing of intellectual property rights for drug candidates.
Sector
Pharmaceuticals
RaQualia Pharma Inc. is a research and development-oriented drug discovery venture with a business model focused on out-licensing intellectual property rights of novel drug candidates to pharmaceutical companies. The company conducts drug discovery research and development for high-need medical conditions, primarily in gastrointestinal and pain disorders. RaQualia Pharma Inc. pursues agile and flexible business activities, offering its entire research and development portfolio for out-licensing at various stages, from early exploration to clinical development. The company actively engages in open innovation-based research and development, addressing a wide range of disease areas through industry-academic collaborations. RaQualia Pharma Inc. has built a research and development portfolio comprising multiple projects, including out-licensing preparation programs, out-licensed programs, and collaborative research programs.